Company intelligence / Profile preview

Cizzle Biotechnology

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Clinical studies indicate high specificity and ~95% sensitivity for detecting early-stage lung cancer using non-invasive CIZ1B biomarker blood tests; the platform is in clinical trial/testing, not yet commercially launched. No revenue generated, operating losses as of end 2023[2][4].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyDiagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

Corepath Laboratories (US-based exclusive development and commercialization for North America, licensing deal)[2]University of York (UK; ongoing research collaboration)ProteoGenix (monoclonal antibody development)[2]

Beyond the preview

Go deeper on Cizzle Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cizzle Biotechnology.

Explore the full profile